2013
Chemoimmunotherapy and Withdrawal of Immunosupression for Monomorphic Posttransplant Lymphoproliferative Disorders
Podoltsev N, Zhang B, Yao X, Bustillo I, Deng Y, Cooper DL. Chemoimmunotherapy and Withdrawal of Immunosupression for Monomorphic Posttransplant Lymphoproliferative Disorders. Clinical Lymphoma Myeloma & Leukemia 2013, 13: 716-720. PMID: 24035715, PMCID: PMC3846604, DOI: 10.1016/j.clml.2013.07.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinFemaleGraft RejectionHumansImmunosuppression TherapyImmunotherapyLymphoproliferative DisordersMaleMiddle AgedOrgan TransplantationPrednisoneRituximabTreatment OutcomeVincristineWithholding TreatmentYoung AdultConceptsReduction of immunosuppressionMonomorphic PTLDMedian progression-free survivalMonomorphic posttransplant lymphoproliferative disorderGraft rejection ratePosttransplant lymphoproliferative disorderTreatment-related mortalityProgression-free survivalMulti-institutional settingGraft lossMedian OSComplete responseLymphoproliferative disordersCurrent guidelinesDisease progressionAggressive typePatientsChemoimmunotherapyPTLDComplete withdrawalImmunosuppressionCombination programStepwise approachWithdrawalExcellent results
2011
Post-Transplantation Lymphoproliferative Disorders (PTLD) Management in Solid Organ Transplantation (SOT) Recipients
Podoltsev N, Bustillo I, Yao X, Liu H, Cooper D. Post-Transplantation Lymphoproliferative Disorders (PTLD) Management in Solid Organ Transplantation (SOT) Recipients. Blood 2011, 118: 4941. DOI: 10.1182/blood.v118.21.4941.4941.Peer-Reviewed Original ResearchReduction of immunosuppressionDiffuse large B-cell lymphomaYale Cancer CenterMonomorphic PTLDPolymorphic PTLDPTLD patientsGraft lossGraft rejectionComplete responseB cellsMedian progression-free survivalSolid organ transplantation recipientsEpstein-Barr virus infectionLarge B-cell lymphomaEBV-negative tumorsGraft loss rateStandard immunosuppressive agentsMedian overall survivalAdvanced stage diseaseConsequence of immunosuppressionEBV-positive lymphomasOrgan transplantation recipientsProgression-free survivalRetrospective cohort trialTime of diagnosis